This site is intended only for healthcare professionals resident in India




Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information



About CRESEMBA®About CRESEMBA®Meet CRESEMBA®CRESEMBA® in the ICUCRESEMBA® in ActionEfficacy EfficacyInvasive AspergillosisEfficacyGuidelines MucormycosisEfficacyGuidelinesSafetySafetyTolerabilityInvasive AspergillosisMucormycosis Safety ProfileSafety ProfileDosingDosingSimple DosingLinear PKs, Low Variability and TDMPractical ConsiderationsReal-world DataReal-world DataReal-world EffectivenessReal-world SafetyResourcesResourcesSummary of Prescribing InformationEventsMaterialsVideos

CRESEMBA® safety profile

  • Hypersensitivity to the active substance or to any of the excipients listed in the Local Product Document

  • Co-administration with ketoconazole, high-dose ritonavir (>200 mg every 12 hours), strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine

  • Patients with familial short QT syndrome

Special warnings and precautions for use1
  • Hypersensitivity to isavuconazole may result in adverse reactions that include:
    hypotension, respiratory failure, dyspnoea, drug eruption, pruritus and rash. Prescribe 
    with caution in patients with hypersensitivity to other azole antifungal agents

  • Infusion-related reactions including hypotension, dyspnoea, dizziness, paraesthesia, nausea and headache have been reported. The infusion should be stopped if these reactions occur

  • Severe cutaneous adverse reactions such as Stevens-Johnson syndrome have been reported during treatment with azole antifungal agents. If a patient develops a severe cutaneous adverse reaction, CRESEMBA® should be discontinued

  • CRESEMBA® is contraindicated in patients with familial short QT syndrome. Caution is warranted when prescribing CRESEMBA® to patients taking medicinal products, such as rufinamide, known to decrease the QT interval

  • Elevated liver transaminases have been reported in clinical studies and rarely required discontinuation of CRESEMBA®. Monitoring of hepatic enzymes should be considered, as clinically indicated. Hepatitis has been reported with azole antifungal agents including CRESEMBA®

  • CRESEMBA® has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks. Patients should be carefully monitored for potential drug toxicity

Drug interactions1
CYP3A4/5 inhibitors
  • Ketoconazole is contraindicated
  • A two-fold increase in isavuconazole exposure was observed with the strong CYP3A4 inhibitor lopinavir/ritonavir
  • A less pronounced effect can be expected with other strong CYP3A4/5 inhibitors
  • No dose adjustment is necessary when co-administered with strong CYP3A4/5 inhibitors; however, caution is advised as adverse drug reactions may increase
CYP3A4/5 inducers
  • Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone may result in mild to moderate decreases in isavuconazole plasma levels
  • Co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk

CYP3A4/5 substrates, including immunosuppressants
  • Isavuconazole can be considered a moderate inhibitor of CYP3A4/5, and systemic exposure to medicinal products metabolised by CYP3A4 may be increased when co-administered with CRESEMBA®
  • Concomitant use of CRESEMBA® with CYP3A4 substrates such as the immunosuppressants tacrolimus, sirolimus or ciclosporin may increase systemic exposure to these medicinal products
  • Appropriate therapeutic drug monitoring and dose adjustment may be necessary during co-administration

CYP2B6 sustrates
  • Isavuconazole is an inducer of CYP2B6
  • Systemic exposure to medicinal products metabolised by CYP2B6 may be decreased when co-administered with CRESEMBA®. Therefore, caution is advised when CYP2B6 substrates, especially medicinal products with a narrow therapeutic index such as cyclophosphamide, are co-administered with CRESEMBA®
  • The use of the CYP2B6 substrate efavirenz with CRESEMBA® is contraindicated because efavirenz is a moderate inducer of CYP3A4/5

P-gp substrates
  • Isavuconazole may increase the exposure of medicinal products that are P-gp substrates 
  • Dose adjustment of medicinal products that are P-gp substrates, especially medicinal products with a narrow therapeutic index such as digoxin, colchicine and dabigatran etexilate, may be needed when concomitantly administered with CRESEMBA®
Fertility, pregnancy and lactation1
  • There are no data from the use of CRESEMBA® in pregnant women
  • Animal studies have shown reproductive toxicity but the potential risk for humans is unknown
  • CRESEMBA® must not be used during pregnancy except in patients with severe or potentially life-threatening fungal infections, in whom isavuconazole may be used if the anticipated benefits outweigh the possible risks to the foetus

Women of childbearing potential
  • CRESEMBA® is not recommended for women of childbearing potential who are not using contraception

  • Available pharmacodynamic/toxicological data in animals have shown excretion of isavuconazole/metabolites in milk
  • Breast-feeding should be discontinued during treatment with CRESEMBA®
  • A risk to newborns and infants cannot be excluded

  • There are no data on the effect of CRESEMBA® on human fertility
  • Studies in animals did not show impairment of fertility in male or female rats
Adverse reactions1
Summary of the safety profile

The frequency of adverse reactions is based on data from 403 patients with invasive fungal infections treated with CRESEMBA® in phase 3 studies.

The most common treatment-related adverse events were:
  • Elevated liver chemistry tests (7.9%)
  • Nausea (7.4%)
  • Vomiting (5.5%)
  • Dyspnoea (3.2%)
  • Abdominal pain (2.7%)
  • Diarrhoea (2.7%)
  • Injection-site reaction (2.2%)
  • Headache (2.0%)
  • Hypokalaemia (1.7%)
  • Rash (1.7%)

Adverse reactions that most often led to permanent discontinuation of CRESEMBA® were:
  • Confusional state (0.7%)
  • Acute renal failure (0.7%)
  • Increased blood bilirubin (0.5%)
  • Convulsion (0.5%)
  • Dyspnoea (0.5%)
  • Epilepsy (0.5%)
  • Respiratory failure (0.5%)
  • Vomiting (0.5%)

Other adverse reactions include hypersensitivity, syncope, heart rhythm disturbances and circulatory collapse. Please refer to the Summary of Product Characteristics for a full list.

Effects on ability to drive and use machines
  • CRESEMBA® has a moderate potential to influence the ability to drive and use machines
  • Patients should avoid driving or operating machinery if they experience symptoms of confusional state, somnolence, syncope and/or dizziness

  • Symptoms reported more frequently at supratherapeutic doses of CRESEMBA® (equivalent to isavuconazole 600 mg/day) evaluated in a QT study than in the therapeutic dose group (equivalent to isavuconazole 200 mg/day dose) included: headache, dizziness, paraesthesia, somnolence, disturbance in attention, dysgeusia, dry mouth, diarrhoea, oral hypoaesthesia, vomiting, hot flush, anxiety, restlessness, palpitations, tachycardia, photophobia and arthralgia
  • In the event of an overdose, initiate supportive treatment. Isavuconazole is not removed by haemodialysis and there is no specific antidote for isavuconazole

AE, adverse event; CYP, cytochrome P.

Prescribing Information:
CRESEMBA® (isavuconazole)


Adapted from Local Product Document of CRESEMBA® (Isavuconazole) version LPDCRE052021.

PP-CRB-IND-0472 July 2022


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.


Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to

For more details on, Who is a Registered medical practitioner*, please visit , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.

PP-DOL-IND-0251 18 JAN 2023
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023